On November 10, 2020 Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended September 30, 2020 (Press release, Adaptive Biotechnologies, NOV 10, 2020, View Source [SID1234570435]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Over the last quarter, we have demonstrated the unique capability of our platform to translate the immune response at scale into data that informs the development of best-in-class, differentiated diagnostic and therapeutic solutions," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This pandemic has highlighted the key role of the immune response in our understanding of disease. COVID-19 is a prime example of the power of our platform to rapidly generate immune-driven solutions to any disease, including what we believe are best-in-class antibodies against the virus."
Recent Highlights
Revenue was $26.3 million for the quarter ended September 30, 2020, representing a 25% increase from the second quarter 2020 and a 1% increase from the third quarter in the prior year.
Clinical sequencing volume increased 58% to 4,023 clinical tests delivered in the third quarter of 2020 compared to the third quarter 2019 and increased 28% compared to the second quarter 2020.
Identified two antibodies against SARS-CoV-2 that neutralize the virus at very low concentrations.
immunoSEQ T-MAP COVID to be used in a subset of patients from clinical trials of two top tier vaccine developers.
Top-line results from a second real-world study, conducted in Italy, demonstrated T-cell testing outperforms serology in identifying past SARS-CoV-2 infections (97% sensitivity versus 77%) supporting launch of T-Detect COVID, a clinical T-cell based test for past infection.
Identified clinical signal for Crohn’s disease for T-Detect pipeline.
Third Quarter 2020 Financial Results
Revenue was $26.3 million for the quarter ended September 30, 2020, representing a 1% increase from the third quarter in the prior year. Sequencing revenue was $11.3 million for the quarter, representing a 3% decrease from the third quarter in the prior year. Development revenue increased to $15.0 million for the quarter, representing a 5% increase from the third quarter in the prior year.
Operating expenses were $63.3 million for the third quarter of 2020, compared to $44.1 million in the third quarter of the prior year, representing an increase of 44%.
Net loss was $36.7 million for the third quarter of 2020, compared to $14.0 million for the same period in 2019.
Adjusted EBITDA (non-GAAP) was a loss of $28.4 million for the third quarter of 2020, compared to a loss of $12.7 million for the third quarter of the prior year.
Cash, cash equivalents and marketable securities was $851.5 million as of September 30, 2020.
2020 Financial Guidance
Adaptive Biotechnologies is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.
Webcast and Conference Call Information
Adaptive Biotechnologies will host a conference call to discuss its third quarter financial results after market close on Tuesday, November 10, 2020 at 4:30 PM Eastern Time. The conference call can be accessed at View Source The webcast will be archived and available for replay at least 90 days after the event.